Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Invivyd, Inc. - Common Stock (NQ:IVVD)

0.5209 +0.0209 (+4.18%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,555,339
Open 0.5100
Bid (Size) 0.5209 (1)
Ask (Size) 0.5400 (4)
Prev. Close 0.5000
Today's Range 0.4731 - 0.5578
52wk Range 0.3546 - 3.147
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors
From Invivyd
Via GlobeNewswire
Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights
From Invivyd
Via GlobeNewswire

Performance

YTD
+8.5%
+8.5%
1 Month
-43.1%
-43.1%
3 Month
+12.9%
+12.9%
6 Month
-42.2%
-42.2%
1 Year
-82.8%
-82.8%

More News

Read More
Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1
From Invivyd
Via GlobeNewswire
(IVVD) - Analyzing Invivyd's Short Interest
Via Benzinga
Top movers in Monday's session
Via Chartmill
These stocks are moving in today's session
Via Chartmill
There are notable gap-ups and gap-downs in today's session.
Via Chartmill
Wondering what's happening in today's pre-market session?
Via Chartmill
FDA Rejects Invivyd's Request To Expand Emergency Authorization For Preventive COVID-19 Antibody For Immunocompromised Patients
Via Benzinga
Exposures COVID-19 Product Safety
FDA Declined Invivyd’s Request to Expand Existing Emergency Use Authorization of PEMGARDA™ (pemivibart) to Include Treatment of Mild-to-Moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Change to the Existing
From Invivyd
Via GlobeNewswire
Top movers in Friday's after hours session
Via Chartmill
Top movers analysis one hour before the close of the markets on 2025-02-21: top gainers and losers in today's session.
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Invivyd to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025
From Invivyd
Via GlobeNewswire
These 5 Health Care Stocks Saw The Sharpest Retail Interest Jump Last Week
Via Stocktwits
Exposures Product Safety
Which stocks are experiencing notable movement on Friday?
Via Chartmill
On Thursday, there are stocks with unusual volume. Let's take a look.
Via Chartmill
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Here are the top movers in Wednesday's session.
Via Chartmill
Invivyd Announces Partnership with Pro Football Coach Jim Harbaugh to Elevate Awareness and Ongoing Impact of COVID-19: Common, Not A Cold
From Invivyd
Via GlobeNewswire
Tuesday's session: most active stocks
Via Chartmill
Unusual volume stocks in Tuesday's session
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Palantir Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Top movers in Monday's session
Via Chartmill

Frequently Asked Questions

Is Invivyd, Inc. - Common Stock publicly traded?
Yes, Invivyd, Inc. - Common Stock is publicly traded.
What exchange does Invivyd, Inc. - Common Stock trade on?
Invivyd, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Invivyd, Inc. - Common Stock?
The ticker symbol for Invivyd, Inc. - Common Stock is IVVD on the Nasdaq Stock Market
What is the current price of Invivyd, Inc. - Common Stock?
The current price of Invivyd, Inc. - Common Stock is 0.5209
When was Invivyd, Inc. - Common Stock last traded?
The last trade of Invivyd, Inc. - Common Stock was at 04/09/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.